Re: Catherine H. Marshall, Alexandra O. Sokolova, Andrea L. McNatty, et al. Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. Eur Urol 2019;76:452-8.

Joaquin Mateo, Suzanne Carreira, Shahneen Sandhu, Susana Miranda, Helen Mossop, Raquel Perez-Lopez, Daniel Nava Rodrigues, Dan Robinson, Aurelius Omlin, Nina Tunariu, Gunther Boysen, Nuria Porta, Penny Flohr, Alexa Gillman, Ines Figueiredo, Claire Paulding, George Seed, Suneil Jain, Christy Ralph, Andrew Protheroe, Syed Hussain, Robert Jones, Tony Elliott, Ursula McGovern, Diletta Bianchini, Jane Goodall, Zafeiris Zafeiriou, Chris T. Williamson, Roberta Ferraldeschi, Ruth Riisnaes, Bernardette Ebbs, Gemma Fowler, Desamparados Roda, Wei Yuan, Yi-Mi Wu, Xuhong Cao, Rachel Brough, Helen Pemberton, Roger A’Hern, Amanda Swain, Lakshmi P. Kunju, Rosalind Eeles, Gerhardt Attard, Christopher J. Lord, Alan Ashworth, Mark A. Rubin, Karen E. Knudsen, Felix Y. Feng, Arul M. Chinnaiyan, Emma Hall, Johann S. de Bono, DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer. The New England Journal of Medicine. ,vol. 373, pp. 1697- 1708 ,(2015) , 10.1056/NEJMOA1506859

Andrew N. Blackford, Stephen P. Jackson, ATM, ATR, and DNA-PK: The Trinity at the Heart of the DNA Damage Response. Molecular Cell. ,vol. 66, pp. 801- 817 ,(2017) , 10.1016/J.MOLCEL.2017.05.015

Yung-Jue Bang, Rui-Hua Xu, Keisho Chin, Keun-Wook Lee, Se Hoon Park, Sun Young Rha, Lin Shen, Shukui Qin, Nong Xu, Seock-Ah Im, Gershon Locker, Phil Rowe, Xiaojin Shi, Darren Hodgson, Yu-Zhen Liu, Narikazu Boku, Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial The Lancet Oncology. ,vol. 18, pp. 1637- 1651 ,(2017) , 10.1016/S1470-2045(17)30682-4

Michael Cecchini, Zenta Walther, Jeffrey L Sklar, Ranjit S Bindra, Daniel P Petrylak, Joseph P Eder, Sarah B Goldberg, Yale Cancer Center Precision Medicine Tumor Board: two patients, one targeted therapy, different outcomes. Lancet Oncology. ,vol. 19, pp. 23- 24 ,(2018) , 10.1016/S1470-2045(17)30916-6

Catherine H Marshall, Alexandra O Sokolova, Andrea L McNatty, Heather H Cheng, Mario A Eisenberger, Alan H Bryce, Michael T Schweizer, Emmanuel S Antonarakis, None, Differential Response to Olaparib Treatment Among Men with Metastatic Castration-resistant Prostate Cancer Harboring BRCA1 or BRCA2 Versus ATM Mutations. European Urology. ,vol. 76, pp. 452- 458 ,(2019) , 10.1016/J.EURURO.2019.02.002